T ransforming growth factor (TGF)-␤ is a growth factor that exerts many regulatory actions. It is known for its role in development, proliferation, migration, differentiation, and extracellular matrix biology, but it is also an important immunomodulator. 1, 2 These functions are best reflected in TGF-␤1-deficient mice, which die in utero or perinatally because of widespread inflammation. 3 Moreover, mice expressing a dominant-negative TGF-␤ receptor II (TGF␤RII) under a T-lymphocyte-specific promotor in which TGF-␤ signaling is specifically blocked in T lymphocytes showed disruption of T-lymphocyte homeostasis and inflammation in many organs. 4 On the other hand, mice with cardiovascular overexpression of TGF-␤1 are embryonically lethal because of abnormal yolk sac vasculogenesis, 5 and adenoviral gene therapy of TGF-␤1 in the balloon-injured rat causes an increased extracellular matrix deposition in intimal lesions. 6 Furthermore, mice overexpressing TGF-␤1 under a liver-or kidney-specific promotor show excessive fibrosis in the targeted organ. 7, 8 Nowadays, atherosclerosis is considered to be a chronic inflammatory disease, and the balance between inflammation and extracellular matrix deposition is thought to be important for the maintenance of plaque stability in humans. 9, 10 Because TGF-␤ is an immunomodulator and a fibrosis modulator, we postulate that TGF-␤ might play a key role in the maintenance of the phenotype of an atherosclerotic plaque.
The first evidence of an important role for TGF-␤ in vascular disease has been obtained from studies in ballooninjured rats. TGF-␤ levels were increased 6 to 24 hours after balloon injury, 11 and TGF-␤ overexpression 6 or inhibition 12 influences the disease process by an alteration of neointima formation, extracellular matrix deposition, or smooth muscle cell proliferation. Consistent with these results is the observation that patients with severe restenosis also exhibit increased serum levels of TGF-␤. 13 In contrast to the large number of data that report a role for TGF-␤ on neointima formation, data regarding the effects of TGF-␤ on primary atherosclerosis are limited. The expression patterns of TGF-␤1 to -␤3 and of TGF-␤ receptor I (TGF␤RI) and TGF␤RII in atherosclerotic plaques are well known, but functional in vivo studies in primary atherosclerosis are sparse. 14, 15 However, the limited in vivo data available suggest a protective role for TGF-␤ in atherosclerosis. Some research, 14 but not all, 16 has reported that advanced plaque cells contain mutations in the type II receptor that disable proper signaling and consequently decrease sensitivity of these cells for TGF-␤. 14 Furthermore, patients suffering from unstable angina exhibited decreased levels of TGF-␤, 17 indicating a correlation of low TGF-␤ levels with advanced atherosclerosis. ApoE-deficient (apoEϪ/Ϫ) mice that were treated with tamoxifen (an anti-estrogen) exhibited increased TGF-␤ levels that were associated with a decrease in initial lesion formation. 18 Furthermore, in mice heterozygous for the deletion of the TGF-␤1 gene (TGF␤1ϩ/Ϫ mice) that were fed a high fat diet exhibited an increased endothelial activation, and lipid infiltration was observed in the vascular wall. 19 Recently, Mallat et al 20 treated apoEϪ/Ϫ mice with a neutralizing antibody against TGF-␤1, -␤2, and -␤3 from weeks 6 to 15. They observed that atherosclerotic lesions contained a high inflammatory cell content and a decreased amount of collagen.
In the present study, we confirm and expand the data of Mallat et al 20 with the use of a different approach. Inhibition of the TGF-␤ pathway with a soluble recombinant TGF␤RII in apoEϪ/Ϫ mice, in an early treatment (weeks 5 to 17) and delayed treatment (weeks 17 to 29) setting, resulted in increased inflammation and decreased plaque fibrosis and was associated with intraplaque hemorrhages and iron and fibrin deposition. No systemic effects of recombinant soluble TGF␤RII (TGF␤RII:Fc) treatment were observed.
Methods

TGF␤RII:Fc Fusion Gene
The recombinant mouse TGF␤RII:Fc fusion gene, containing the extracellular domain of the mouse type II TGF-␤ receptor fused to the Fc portion of mouse IgG2a, was constructed as described previously. 21 TGF␤RII:Fc was purified, and its activity was tested in mink lung epithelial cells (Mv1Lu). 21 In vivo studies confirmed the effectiveness the TGF␤RII:Fc. 22, 23 Mice ApoEϪ/Ϫ (male, nϭ36) mice on a C57Bl6 background were obtained from Iffa Credo (Lyon, France). Mice were injected with TGF␤RII:Fc fusion protein or the control mouse IgG twice a week for 12 weeks (100 g/wk IP). The dosing regimen used in the present study was based on earlier in vivo studies using the same compound. 22, 23 Treatment started at the age of 5 weeks (early treatment, nϭ10 TGF␤RII:Fc mice and nϭ10 control mice) or at the age of 17 weeks (delayed treatment, nϭ8 TGF␤RII:Fc mice and nϭ8 control mice). After the experimental procedure, mice were euthanized after a 24-hour fast. Blood (0.5 to 1 mL) was obtained from the caval vein for lipoprotein analysis. The arterial tree was perfused, and the aortic arch, including its main branch points (brachiocephalic trunk, left common carotid artery, and left subclavian artery), was excised and fixed as described previously. 24, 25 The aortic arch including branch points was embedded longitudinally and cut into Ϸ40 sections. A series of twenty 4-m sections, which represented the central area of the arch with an intact morphology of the complete arch and branch points, were analyzed. 24, 25 Lipid Profile 
Evaluation of Possible Systemic Effects
To evaluate possible systemic effects of TGF␤RII:Fc treatment, fluorescence-activated cell sorter (FACS) analysis (FACS calibur, Beckton Dickinson) with T-cell-specific antibodies was performed on spleen and lymph nodes of TGF␤RII:Fc-treated (nϭ3) and control (nϭ3) mice of the delayed treatment group. Antibodies used for staining were anti-CD3 FITC and biotinylated CD4, CD8 , CD45RB FITC , and CD25 PE (all Pharmingen). In addition, Ͼ20 organs from each mouse (nϭ34 mice) were excised and analyzed on 4-m sections stained with hematoxylin and eosin and with CD45.
Histology and Morphometry
For histological analysis of atherosclerosis, 4 sections (20 m apart) were stained with hematoxylin and eosin. Atherosclerotic lesions were analyzed and classified according to American Heart Association (AHA) criteria. 26 To obtain precise insights of the effects of TGF␤RII:Fc treatment on plaque progression, all analyses were performed on separate lesion types, representing all stages of atherogenesis, as defined by the AHA. Because the data on plaque burden and inflammatory and fibrotic parameters between the separate early plaque stages (AHA type I, II, and III lesions) as well as between the separate advanced stages (type IV and V lesions) were similar, data were presented in 2 groups: initial lesions (AHA type I/II/III) and advanced lesions (AHA type IV/V). 26, 27 Morphometric parameters were determined as described previously. 24 
Immunohistochemistry
Sections were immunolabeled with the following: ␣-smooth muscle actin (ASMA FITC monoclonal antibody, 1:500; Sigma) as a marker for vascular smooth muscle cells and fibroblasts; Mac3 (1:30, Pharmingen) to detect macrophages; CD3 polyclonal antibody (A0452, 1:200; Dako) to detect T lymphocytes; CD45 (1:30, Pharmingen) to detect inflammatory cells; CD40 (1:30, Santa Cruz), CD40L (1:30, Santa Cruz), TGF-␤ (1:30, R&D Systems), factor VIII (1:500, Dako), and fibrin(ogen) (1:800, Nordic Immunologies); and matrix metalloproteinase (MMP)-2 and MMP-9 (both 1:20), as described. 24, 25 Perls' stain was used to detect iron. The relative amounts of cells were determined as described previously. 24 All measurements were performed by 2 independent investigators who were blinded regarding treatment group. Intraobserver as well as interobserver variation was Ͻ10%.
Signaling
To obtain more insight into the effects of TGF␤RII:Fc treatment on downstream signaling effects, immunohistochemistry with antibodies against Smad2 (goat polyclonal antibody, 1:100; Santa Cruz), Smad3 (goat polyclonal antibody, 1:10; Santa Cruz), phosphoSmad2/3 (rabbit polyclonal antibody, 1:500; Santa Cruz), Smad4 (goat polyclonal antibody, 1:20; Santa Cruz), and Smad7 (goat polyclonal antibody, 1:100; Santa Cruz) was used.
Statistical Analysis
Data are expressed as meanϮSEM. TGF␤RII:Fc-treated apoEϪ/Ϫ mice were compared with control apoEϪ/Ϫ mice by a nonparametric Mann-Whitney U test. Data were considered statistically significant at PϽ0.05.
Results
Mouse Study: General
Survival rates were 100% in the early treatment study and 87.5% in both groups of the delayed treatment study. Body weight and heart weight did not differ between the treatment groups, nor did the levels of plasma cholesterol (early treatment, 13 
Signaling
In atherosclerotic plaques of the early and delayed TGF␤RII:Fc treatment groups, immunoreactivity of Smad2 and phospho-Smad2/3 (please see online Figure IIIa and IIIb, which can be accessed at www.ahajournals.org) decreased, whereas immunoreactivity of Smad3, Smad4, and Smad7 did not change. The decrease in phospho-Smad2/3 and the decrease in Smad2 indicate the in vivo inhibition of TGF-␤ signaling.
Plaque Burden
We analyzed 43 lesions in the aortic arches of TGF␤RII:Fctreated apoEϪ/Ϫ mice (nϭ10) and 47 lesions of the control mice (nϭ10) in the early treatment study and 40 lesions in the aortic arches of TGF␤RII:Fc-treated apoEϪ/Ϫ mice (nϭ7) and 41 lesions of the control mice (nϭ7 mice) in the delayed treatment study. In the early treatment study, total plaque burden was not affected. However, in the delayed treatment study, total plaque area of the aortic arch decreased 37 (Figure 1a and 1b) . Interestingly, TGF␤RII:Fc treatment altered the distribution of AHA lesion types. In the early treatment group, the absolute and relative amounts of type Va lesions increased after TGF␤RII:Fc treatment (72.7% for TGF␤RII:Fc versus 30% for control, as percentage of all advanced lesions), whereas the absolute and relative amounts of type IV lesions (18.2% for TGF␤RII:Fc versus 70% for control, as percentage of all advanced lesions) had decreased. Similar results were obtained in the delayed treatment group (Figure 1c  and 1d) . In that group, the number of Va lesions (fibrous cap and large lipid core) had increased (64.0% for TGF␤RII:Fc versus 39.1% for control), whereas the number of Vc lesions (fibrous lesions) was decreased (8% for TGF␤RII:Fc versus 30.4% for control). This indicates that TGF␤RII:Fc treatment induces a plaque phenotype with large lipid cores and thin fibrous caps. Individual plaque area per lesion type had significantly decreased in type IV lesions of the early treatment study and in type V lesions of the delayed treatment study (Figure 1c and 1d) .
Plaque Composition
Besides the decrease in plaque area, the composition of the plaques significantly differed after TGF␤RII:Fc treatment compared with control treatment.
Initial Atherosclerotic Plaques (Fatty Streaks)
Further analysis of initial lesion development in the aortic arch revealed that the relative and absolute numbers of CD3-positive cells (T lymphocytes) increased after TGF␤RII:Fc treatment: relative numbers were 5.0Ϯ1.0% for TGF␤RII:Fc versus 1.8Ϯ1.2% for control (PϽ0.05) for early treatment and 4.9Ϯ0.6% for TGF␤RII:Fc versus 2.0Ϯ1.0% for control (PϽ0.05) for late treatment; absolute numbers were 10Ϯ3 for TGF␤RII:Fc versus 3Ϯ1 for control for early treatment and 2Ϯ1 for TGF␤RII:Fc versus 1Ϯ0 for control for late treatment). The relative and absolute numbers of CD45-positive cells also increased after TGF␤RII:Fc treatment: relative numbers are shown in Figure 1e ; absolute numbers were 3Ϯ1 for TGF␤RII:Fc versus 1Ϯ0 for control for early treatment and 9Ϯ4 for TGF␤RII:Fc versus 2Ϯ1 for control for late treatment. Furthermore, CD40 and CD40L immunoreactivity in initial lesions of the early treatment and delayed treatment studies also increased after TGF␤RII:Fc treatment. Macrophage content decreased in initial lesions of the treated mice of the early treatment study (82.1Ϯ2.2% for TGF␤RII:Fc versus 73.5Ϯ2.0% for control, PϽ0.05; delayed treatment, 74.4Ϯ5.6% for TGF␤RII:Fc versus 70.8Ϯ3.4% for control, PϾ0.05). Collagen content (Figure 1f ), ␣-smooth muscle actin content (early treatment, 0.4Ϯ0.2% for TGF␤RII:Fc versus 0.9Ϯ0.5% for control, PϾ0.05; delayed treatment, 0.7Ϯ0.5% for TGF␤RII:Fc versus 0.8Ϯ0.8% for control), and MMP-2 and MMP-9 immunoreactivity did not differ.
Advanced Atherosclerotic Plaques
In advanced lesions, the effects of inhibition of TGF-␤ signaling on plaque composition were even more pronounced. Lipid cores of the TGF␤RII:Fc treatment group were 84.2% and 64.6% larger than in control-treated mice,
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respectively (Figures 1g, 2a, and 2b) , and lipid core expansion was accelerated (148.2% versus 50% increase in lipid core content from weeks 17 to 29, PϽ0.05; Figure 1g ). (Figures 1e, 2c , and 2d; absolute numbers for early treatment were 6Ϯ1 for TGF␤RII:Fc versus 2Ϯ1 for control; absolute numbers for delayed treatment were 12Ϯ2 for TGF␤RII:Fc versus 6Ϯ1 for control). CD40 and CD40L (Figures 2e and 2f ) immunoreactivity was also significantly increased after TGF␤RII:Fc treatment. In addition, the amount of fibrosis, reflected by the collagen content, had decreased 50.3% in the delayed treatment study (Figures  1f, 2g, and 2h ). MMP-2 and MMP-9 immunoreactivity was increased. The amount of ␣-smooth muscle actin-positive Interestingly, the increase in inflammation and decrease in fibrosis in plaques of mice treated with TGF␤RII:Fc were associated with a significant increase in the frequencies of recent and older intraplaque bleedings and fibrin and iron deposition in the delayed treatment group (Figures 1h and 3) . This was not associated with acute ischemic events.
These data show that blockade of TGF-␤ signaling decreases the advanced plaque area and alters the balance between plaque inflammation and fibrosis. This results in an inflammatory plaque phenotype with a low extracellular matrix content. Systemic effects, as well as changes in lipid profile, were not observed.
Discussion
In accordance with the present results, Mallat et al 20 also reported that inhibition of TGF-␤ in primary atherosclerosis induces an increase in plaque inflammation and a decrease in plaque fibrosis. However, besides these similarities in outcome, there are also important differences between both studies. First of all, we used a different kind of TGF-␤ blockade. Whereas Mallat et al treated the mice with an inhibiting antibody against TGF-␤1, -␤2, and -␤3, we used a soluble recombinant TGF␤RII. Second, besides the early time points that were studied by Mallat et al (treatment weeks 6 to 15) and us (treatment weeks 5 to 17), we also studied the effects of TGF-␤ blockade after 29 weeks. In this delayed treatment group, we were able to show that the increase in plaque inflammation and decrease in plaque fibrosis were associated with intraplaque hemorrhages and iron and fibrin Our results are in agreement with the data earlier reported in in vitro studies. These studies show that TGF-␤ functions as an anti-inflammatory cytokine in cell types that are also present in atherosclerotic plaques. [31] [32] [33] TGF-␤ is also known to be an important fibrotic cytokine that plays an important role in matrix remodeling and collagen synthesis. 34 The signaling cascade by which TGF-␤ exerts its actions is well known. In brief, TGF-␤ binds via receptor III to receptor II or directly to receptor II, and this complex binds to receptor I. This induces the phosphorylation of Smad2 or Smad3. Subsequently, phospho-Smad-2 or -Smad-3 binds to Smad-4, and the resulting complex moves to the nucleus, where it interacts with various transcription factors to regulate the transcription of TGF-␤-responsive genes and mediates the effects of TGF-␤ at the cellular level. 2 In the present study, it was shown that TGF␤RII:Fc treatment suppresses phosphorylation of Smad2/3, thereby inhibiting the actions of TGF-␤.
The phenomenon that inhibition of inflammation causes a plaque phenotype that contains a high extracellular matrix content has been described previously. Genetic disruption of interferon-␥ in apoEϪ/Ϫ mice has been reported to result in smaller atherosclerotic plaques with higher collagen content. 35 Furthermore, we and others observed a collagen-rich phenotype after inhibition of CD40L in apoEϪ/Ϫ and LDL receptor-deficient mice. 24, 25, 36 Overexpression of the antiinflammatory cytokine interleukin-10 increased collagen content in atherosclerotic lesions, whereas inhibition of interleukin-10 decreased collagen content. 37, 38 Our earlier reports suggested the importance of TGF-␤ as a mediator of plaque fibrosis. Inhibition of CD40L signaling in atherosclerosis resulted in a lipid-poor collagen-rich plaque phenotype. Interestingly, we observed an increased immunoreactivity of TGF-␤ in these lesions. 25, 39 Additional analysis with a cDNA expression array revealed that anti-CD40L treatment induced a 2.3-fold upregulation of TGF-␤ mRNA. These results suggest that upregulation of TGF-␤ may be associated with the CD40L inhibition-induced fibrotic plaque phenotype. The observed balance between CD40L and TGF-␤ and the effects on plaque phenotype observed after CD40L (fibrosis-rich inflammatory-poor plaque phenotype) or TGF␤RII inhibition (inflammatory-rich fibrosis-poor plaque phenotype) reflect the importance of the balance between inflammation and fibrosis on atherosclerotic plaque phenotype.
The results of the present study suggest that TGF-␤ may be used as a therapeutic target. However, whether TGF-␤ treatment would be beneficial or detrimental still needs to be determined. On the one hand, TGF-␤ would induce plaques with a high extracellular matrix content and a low inflammatory cell content, which may help to stabilize the plaque. On the other hand, the possible drawbacks of administration of TGF-␤ may be possible systemic fibrotic effects and an increase in plaque size. Targeted administration of TGF-␤ may solve the first problem. A role for TGF-␤ in atherosclerotic plaque growth has been postulated previously. Immunohistochemical analysis revealed that TGF-␤ and TGF␤RII are most abundant in initial lesions and lesions with pathological intimal thickening and may stimulate the production of lipid-trapping proteoglycans. 40 -42 In other models of neointima formation, such as the balloon-injured rat, TGF-␤ also induced neointimal growth, and inhibition of TGF-␤-signaling was able to significantly reduce neointima formation. 12 A decrease in plaque size is beneficial in preventing clinical symptoms of atherosclerosis. However, because in humans, plaque composition is a more important predictor of the acute vascular symptoms than is plaque size, 27,43 one may hypothesize that inhibition of TGF-␤ may increase plaque instability and evoke more clinical symptoms, even when plaque size decreases. Thus, local activation of TGF-␤-signaling may provide a therapeutical target in atherosclerosis. Although it may not prevent the initiation of atherosclerosis, it may prevent the transition into an unstable plaque phenotype because of its anti-inflammatory and profibrotic effects.
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